• SENSEX
    NIFTY 50
Business

Biocon share price shoots up on Q1 numbers and biologics business

Updated : July 27, 2018 04:11 PM IST

Biocon's contract research and manufacturing arm, Syngene International, reported a 39 percent YoY growth.
Biocon–Mylan received approval for two biosimilar drugs pegfilgrastim and trastuzumab in the past seven months, marking their entry in to the coveted US biosimilar market.
Biocon share price shoots up on Q1 numbers and biologics business

You May Also Like

Live TV

recommended for you

Advertisement